-
Je něco špatně v tomto záznamu ?
Presence and extent of lymphovascular invasion in surgical stage I squamous cell carcinoma of the cervix: a comprehensive, international, multicentre, retrospective clinicopathological study
S. Stolnicu, D. Allison, B. Tessier-Cloutier, A. Momeni-Boroujeni, L. Hoang, A. Ieni, A. Felix, C. Terinte, A. Pesci, C. Mateoiu, A. Hodgson, E. Guerra, L. de Brot, RR. Lastra, T. Kiyokawa, R. Ali-Fehmi, M. Kheil, P. Dundr, A. Roma, O. Fadare, G....
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, multicentrická studie
- MeSH
- cervix uteri patologie chirurgie MeSH
- dospělí MeSH
- invazivní růst nádoru MeSH
- lidé středního věku MeSH
- lidé MeSH
- lymfatické metastázy patologie MeSH
- nádory děložního čípku * patologie chirurgie mortalita MeSH
- prognóza MeSH
- retrospektivní studie MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- spinocelulární karcinom * patologie chirurgie mortalita MeSH
- staging nádorů * MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
The aim of this study was to determine whether the presence and extent of lymphovascular invasion (LVI) is prognostic in surgical stage I cervical squamous cell carcinoma (SCC). All available tumour slides and/or paraffin blocks from 426 patients with stage I cervical SCC treated surgically with curative intent were collected from 18 institutions and retrospectively analysed. Presence and extent of LVI (focal <5 spaces, extensive ≥5 spaces) were assessed on scanning magnification in large haematoxylin and eosin slide sets in 366 cases. Progression-free survival (PFS) was calculated as the time from surgery to first progression or death or last follow-up, whichever occurred first. Overall survival (OS) was defined as the time from surgery to death or last follow-up. Clinicopathological and statistical analyses were performed on 97 patients with the International Federation of Gynecology and Obstetrics (FIGO) 2018 stage IA and 329 patients with stage IB SCC of the cervix. LVI, both focal and extensive, was more frequent in stage IB than in stage IA (p<0.001). Patients with stage IB carcinomas with extensive LVI had worse PFS [hazard ratio (HR) 2.86; 95% confidence interval (CI) 1.49, 5.49; p=0.005] and OS (HR 2.88; 95% CI 1.38, 6.02; p=0.012) than those with focal or no LVI. In stage IA, in contrast, the presence and extent of LVI did not associate with PFS (p=0.926) or OS. Extensive LVI was not statistically correlated with PFS and OS in substages IA1, IA2 or IB2. PFS (HR 3.7; 95% CI 1.61, 8.46; p<0.001) and OS (HR 4.18; 95% CI 1.58, 11.04; p=0.002) in stage IB1, and PFS (HR 7.78; 95% CI 0.87, 69.82; p=0.039) in stage IB3 were diminished in the presence of extensive LVI. In conclusion, in patients with FIGO stage I cervical SCC, the presence and extent of LVI has prognostic significance in stage IB carcinoma, and quantifying LVI is recommended.
Department of Pathology A C Camargo Cancer Center Sao Paulo Brazil
Department of Pathology and Laboratory Medicine Emory University School of Medicine Atlanta USA
Department of Pathology Cleveland Clinic Cleveland USA
Department of Pathology Hospital Universitari de Bellvitge IDIBELL Barcelona Spain
Department of Pathology Laboratory Medicine Program University Health Network Toronto Canada
Department of Pathology Massachusetts General Hospital Boston MA USA
Department of Pathology Memorial Sloan Kettering Cancer Center New York NY USA
Department of Pathology Oncologic Institute Lisbon Portugal
Department of Pathology Sahlgrenska University Hospital Gothenburg Sweden
Department of Pathology Universita degli Studi di Messina Italy
Department of Pathology University of California San Diego USA
Department of Pathology University of Chicago Chicago IL USA
Department of Pathology University of Michigan Detroit MI USA
Department of Pathology Vancouver General Hospital Vancouver BC Canada
Department of Pathology Wayne University Detroit MI USA
Department of Surgical Oncology A C Camargo Cancer Center Brazil
Jikei University School of Medicine Tokyo Japan
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25010110
- 003
- CZ-PrNML
- 005
- 20250429134812.0
- 007
- ta
- 008
- 250415s2025 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.pathol.2024.07.008 $2 doi
- 035 __
- $a (PubMed)39477763
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Stolnicu, Simona $u Department of Pathology, University of Medicine, Pharmacy, Science and Technology 'George E Palade' of Targu Mures, Targu Mures, Romania. Electronic address: simonastolnicu@icloud.com
- 245 10
- $a Presence and extent of lymphovascular invasion in surgical stage I squamous cell carcinoma of the cervix: a comprehensive, international, multicentre, retrospective clinicopathological study / $c S. Stolnicu, D. Allison, B. Tessier-Cloutier, A. Momeni-Boroujeni, L. Hoang, A. Ieni, A. Felix, C. Terinte, A. Pesci, C. Mateoiu, A. Hodgson, E. Guerra, L. de Brot, RR. Lastra, T. Kiyokawa, R. Ali-Fehmi, M. Kheil, P. Dundr, A. Roma, O. Fadare, G. Turashvili, E. Oliva, KM. Devins, G. Baiocchi, D. Cibula, RA. Soslow
- 520 9_
- $a The aim of this study was to determine whether the presence and extent of lymphovascular invasion (LVI) is prognostic in surgical stage I cervical squamous cell carcinoma (SCC). All available tumour slides and/or paraffin blocks from 426 patients with stage I cervical SCC treated surgically with curative intent were collected from 18 institutions and retrospectively analysed. Presence and extent of LVI (focal <5 spaces, extensive ≥5 spaces) were assessed on scanning magnification in large haematoxylin and eosin slide sets in 366 cases. Progression-free survival (PFS) was calculated as the time from surgery to first progression or death or last follow-up, whichever occurred first. Overall survival (OS) was defined as the time from surgery to death or last follow-up. Clinicopathological and statistical analyses were performed on 97 patients with the International Federation of Gynecology and Obstetrics (FIGO) 2018 stage IA and 329 patients with stage IB SCC of the cervix. LVI, both focal and extensive, was more frequent in stage IB than in stage IA (p<0.001). Patients with stage IB carcinomas with extensive LVI had worse PFS [hazard ratio (HR) 2.86; 95% confidence interval (CI) 1.49, 5.49; p=0.005] and OS (HR 2.88; 95% CI 1.38, 6.02; p=0.012) than those with focal or no LVI. In stage IA, in contrast, the presence and extent of LVI did not associate with PFS (p=0.926) or OS. Extensive LVI was not statistically correlated with PFS and OS in substages IA1, IA2 or IB2. PFS (HR 3.7; 95% CI 1.61, 8.46; p<0.001) and OS (HR 4.18; 95% CI 1.58, 11.04; p=0.002) in stage IB1, and PFS (HR 7.78; 95% CI 0.87, 69.82; p=0.039) in stage IB3 were diminished in the presence of extensive LVI. In conclusion, in patients with FIGO stage I cervical SCC, the presence and extent of LVI has prognostic significance in stage IB carcinoma, and quantifying LVI is recommended.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a nádory děložního čípku $x patologie $x chirurgie $x mortalita $7 D002583
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 12
- $a spinocelulární karcinom $x patologie $x chirurgie $x mortalita $7 D002294
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 12
- $a staging nádorů $7 D009367
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a lymfatické metastázy $x patologie $7 D008207
- 650 _2
- $a invazivní růst nádoru $7 D009361
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a cervix uteri $x patologie $x chirurgie $7 D002584
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 700 1_
- $a Allison, Douglas $u Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
- 700 1_
- $a Tessier-Cloutier, Basile $u Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
- 700 1_
- $a Momeni-Boroujeni, Amir $u Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
- 700 1_
- $a Hoang, Lien $u Department of Pathology, Vancouver General Hospital, Vancouver, BC, Canada
- 700 1_
- $a Ieni, Antonio $u Department of Pathology, Universita degli Studi di Messina, Italy
- 700 1_
- $a Felix, Ana $u Department of Pathology, Oncologic Institute, Lisbon, Portugal
- 700 1_
- $a Terinte, Cristina $u Regional Institute of Oncology, Iasi, Romania
- 700 1_
- $a Pesci, Anna $u Ospedale Sacro Cuore Don Calabria, Negrar, Italy
- 700 1_
- $a Mateoiu, Claudia $u Department of Pathology, Sahlgrenska University Hospital, Gothenburg, Sweden
- 700 1_
- $a Hodgson, Anjelica $u Department of Pathology, Laboratory Medicine Program, University Health Network, Toronto, Canada
- 700 1_
- $a Guerra, Esther $u Department of Pathology, Hospital Universitari de Bellvitge-IDIBELL, Barcelona, Spain
- 700 1_
- $a de Brot, Louise $u Department of Pathology, A.C. Camargo Cancer Center, Sao Paulo, Brazil
- 700 1_
- $a Lastra, Ricardo R $u Department of Pathology, University of Chicago, Chicago, IL, USA
- 700 1_
- $a Kiyokawa, Takako $u Jikei University School of Medicine, Tokyo, Japan
- 700 1_
- $a Ali-Fehmi, Rouba $u Department of Pathology, University of Michigan, Detroit, MI, USA
- 700 1_
- $a Kheil, Mira $u Department of Pathology, Wayne University, Detroit, MI, USA
- 700 1_
- $a Dundr, Pavel $u Department of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic
- 700 1_
- $a Roma, Andres $u Department of Pathology, University of California, San Diego, USA
- 700 1_
- $a Fadare, Oluwole $u Department of Pathology, University of California, San Diego, USA
- 700 1_
- $a Turashvili, Gulisa $u Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, USA
- 700 1_
- $a Oliva, Esther $u Department of Pathology, Massachusetts General Hospital, Boston, MA, USA
- 700 1_
- $a Devins, Kyle M $u Department of Pathology, Massachusetts General Hospital, Boston, MA, USA
- 700 1_
- $a Baiocchi, Glauco $u Department of Surgical Oncology, A.C.Camargo Cancer Center, Brazil
- 700 1_
- $a Cibula, David $u Department of Gynaecology, Obstetrics and Neonatology, General University Hospital in Prague, First Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Soslow, Robert A $u Department of Pathology, Cleveland Clinic, Cleveland, USA
- 773 0_
- $w MED00003708 $t Pathology $x 1465-3931 $g Roč. 57, č. 1 (2025), s. 17-26
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39477763 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250415 $b ABA008
- 991 __
- $a 20250429134807 $b ABA008
- 999 __
- $a ok $b bmc $g 2311467 $s 1247191
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 57 $c 1 $d 17-26 $e 20240930 $i 1465-3931 $m Pathology $n Pathology $x MED00003708
- LZP __
- $a Pubmed-20250415
